Photobiomodulation in sleep has more therapeutic effects for Alzheimer’s disease than in wakefulness
It is well known that sleep is the best medication. However, it is still unknown why the brain recovers better in sleep and whether these processes can be controlled. Recent discoveries have shown that the lymphatic system of the brain is activated during sleep, which contributes to the removal of metabolites, toxins and unnecessary molecules from its tissues. Sleep disturbance contributes to the deposition of metabolites in the central nervous system (CNS). For example, sleep is a biomarker for the development of Alzheimer’s disease. This is due to the fact that the toxic metabolite beta-amyloid is excreted from brain tissue during sleep. Sleep deprivation leads to the accumulation of toxin in the CNS, which over time can lead to the development of Alzheimer’s disease.
In this pilot study, the researchers have shown that non-invasive sleep photobiomodulation technology can effectively increase lymphatic excretion of beta-amyloid from the brain tissues of mice with Alzheimer’s disease. At the same time, photobiomodulation in sleep has more significant therapeutic effects than in wakefulness. Photobiomodulation during sleep turns the brain into a washing machine, helping to cleanse its tissues of toxic beta-amyloid and increase resistance to the progression of Alzheimer’s disease. The work entitled “Mechanisms of phototherapy of Alzheimer’s disease during sleep and wakefulness: the role of the meningeal lymphatics” was published on Frontiers of Optoelectronics (published on Sep. 18, 2023).
Semyachkina-Glushkovskaya, O., et al. (2023). Mechanisms of phototherapy of Alzheimer’s disease during sleep and wakefulness: the role of the meningeal lymphatics. Frontiers of Optoelectronics. doi.org/10.1007/s12200-023-00080-5.
